VYNE Therapeutics Inc.
NASDAQ Global SelectTotal Valuation
VYNE Therapeutics Inc. carries a market capitalization of 19.07M, placing it among publicly traded companies globally. Its enterprise value stands at 971.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 19.07M |
| Enterprise Value | 971.66M |
Share Statistics
VYNE Therapeutics Inc. currently has 33.35M shares outstanding.
| Shares Outstanding | 33.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2,815.30, and the price-to-book ratio stands at 40.45.
| PE Ratio | N/A |
| PS Ratio | 2,815.30 |
| PB Ratio | 40.45 |
| P/TBV Ratio | 40.45 |
| P/FCF Ratio | -49.65 |
| P/OCF Ratio | -49.65 |
Enterprise Valuation
| EV / Sales | 2,140.21 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
VYNE Therapeutics Inc. maintains a current ratio of 20.86, meaning it holds 20.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 20.86 |
| Quick Ratio | 20.17 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -62.40 |
| Return on Assets (ROA) | -52.15 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 4,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
VYNE Therapeutics Inc.'s stock has gained approximately 79.84887% over the past 52 weeks. The 50-day moving average sits at 34.03, while the 200-day moving average is 28.60.
| Beta (5Y) | N/A |
| 52-Week Price Change | 79.84887% |
| 50-Day Moving Average | 34.03 |
| 200-Day Moving Average | 28.60 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, VYNE Therapeutics Inc. generated 454,000.00 in revenue and converted that into -21.46M in net income, yielding earnings per share of -0.51. EBITDA reached -24.35M, while operating income came in at -24.37M.
| Revenue | 454,000.00 |
| Gross Profit | N/A |
| Operating Income | -24.37M |
| Pretax Income | -21.71M |
| Net Income | -21.46M |
| EBITDA | -24.35M |
| EBIT | -24.37M |
| Earnings Per Share (EPS) | -0.51 |
Balance Sheet
Total book value stands at 24.64M, with working capital of 24.55M providing operational flexibility.
| Cash & Cash Equivalents | 24.93M |
| Total Debt | N/A |
| Net Debt | -24.63M |
| Equity (Book Value) | 24.64M |
| Book Value Per Share | 0.74 |
| Working Capital | 24.55M |
Cash Flow
VYNE Therapeutics Inc. produced -25.74M in operating cash flow over the past twelve months.
| Operating Cash Flow | -25.74M |
| Capital Expenditures | N/A |
| Free Cash Flow | -25.74M |
| FCF Per Share | -0.60 |
Margins
VYNE Therapeutics Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -5,367.62 and net profit margin of -4,726.21 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -5,367.62 |
| Pretax Margin | -4,782.82 |
| Profit Margin | -4,726.21 |
| EBITDA Margin | -5,362.56 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.01 |
| FCF Yield | -2.01 |
Stock Splits
VYNE Therapeutics Inc.'s most recent stock split took place on July 27, 2026 with a 50:1 split ratio.
| Last Split Date | 7/27/2026 |
| Split Ratio | 50:1 |
Scores
VYNE Therapeutics Inc. posts an Altman Z-Score of 440.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 440.64 |